Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

The design of novel inhibitors to target BACE1 with reduced cytotoxicity effects is a promising approach to treat Alzheimer's disease (AD). Multiple clinical drugs and antibodies such as AZD3293 and Solanezumab are being tested to investigate their therapeutical potential against AD. The curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Mubashir, Shahzadi, Saba, Seo, Sung Y., Alashwal, Hany, Zaki, Nazar, Moustafa, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992503/
https://www.ncbi.nlm.nih.gov/pubmed/29910719
http://dx.doi.org/10.3389/fncom.2018.00034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992503/
https://www.ncbi.nlm.nih.gov/pubmed/29910719
http://dx.doi.org/10.3389/fncom.2018.00034

Ejemplares similares